We investigated the effectiveness of RPL554 a dual phosphodiesterase 3 and 4 enzyme inhibitor, on airway smooth muscle relaxation and compared it to that induced by salbutamol, ipratropium bromide, glycopyrrolate or their combination on bronchomotor tone induced by different spasmogenic agents.
Introduction
Bronchodilators including beta2-agonists and muscarinic receptor antagonists are used in acute and maintenance therapy of respiratory conditions including asthma and COPD (Barnes, 2011; Cazzola et al., 2012) . The clinical effectiveness of these bronchodilators may be reduced with both increased disease severity and also during exacerbation of disease symptoms. Hence, there is a need to increase the magnitude of bronchodilation to obtain greater clinical benefit. One approach is the administration of long acting beta2-agonists and muscarinic receptor antagonists in combination (Tashkin & Ferguson, 2013; Spina, 2014) .
Similarly, the combination of ipratropium bromide with the short acting beta2-agonist, salbutamol is often used in the management of acute asthma, although the added benefit of the combination over salbutamol alone is questionable (FitzGerald et al., 1997; Garrett et al., 1997) .
We have previously reported the clinical effectiveness and absence of significant adverse clinical effects such as nausea, emesis and cardiovascular liability of RPL554 the dual phosphodiesterase (PDE) 3 and 4 inhibitor in patients with asthma and COPD (Franciosi et al., 2013) . The increases in FEV 1 observed with this drug are likely a consequence of relaxation and functional antagonism of airway tone as demonstrated in guinea-pig isolated trachea (Boswell-Smith et al., 2006) and human bronchial airways (Calzetta et al., 2013; Calzetta et al., 2015) .
Sustained bronchoconstriction can lead to airway closure which is associated with an increase in disease severity, and risk of exacerbation (Gibbons et al., 1996; Lee et al., 2001 ).
The use of inhaled bronchodilators during an acute exacerbation of disease can ameliorate the effect of increased smooth muscle tone on airway closure, but comparable or additional improvement in clinical indices of symptoms can also be achieved with concomitant treatment with intravenous theophylline (Ream et al., 2001; Wheeler et al., 2005) or the PDE3 selective inhibitor enoximone (Beute, 2014) additional to standard care with bronchodilators and glucocorticosteroids. Phosphodiesterase inhibitors, particularly dual acting inhibitors like RPL554, may also have greater functional antagonistic properties than standard inhaled bronchodilators that could provide additional benefit, particularly during an exacerbation of asthma.
We have hypothesised that RPL554 may offer additional bronchodilation in severely constricted airways and therefore could provide an adjunct to current treatment modalities in the clinic. In this study, we show that RPL554 produced a greater maximal relaxation compared with standard bronchodilators administered alone or combined during different experimental conditions to increase bronchomotor tone. In addition RPL554 enhanced the relaxant effect caused by the combination of salbutamol and anti-cholinergic agents.
Furthermore, this airway smooth muscle relaxant profile exhibited by RPL554 appears to be unique and not merely the sum of the addition of a selective PDE3 (e.g. cilostamide) and a selective PDE4 inhibitor (e.g. roflumilast).
Methodology Group Sizes
Group sizes are specified in the tables and figures and represent the number of animals used.
Exact group sizes are shown in the tables and figures. In some instances, group sizes appear unequal as variables were taken from different experiments to calculate the overall global mean potency and Emax value for a particular drug under the same experimental conditions.
In one instance (Table 1) , potency values for some drugs were calculated from N=3 and 4 and served to give a qualitative measure of drug potency and no formal statistical analysis was performed.
Randomization
There was no formal randomization of tracheal tissue to organ baths, but rather the chance allocation of tracheal preparations to organ baths on any experimental day. In a similar fashion there was no formal randomization of spasmolytic to tissue preparation from the same animal in view of the fact that multiple tracheal tissue preparations were obtained from the sample animal. The observational unit was the animal.
Blinding
It was not possible to blind the operator to each spasmolytic agent applied to each organ bath.
The concentration ranges varied between spasmolytic agents hence making it impossible to blind to treatment. The variables measured were not of a subjective nature, rendered blinding in this case unnecessary.
Normalization
Relaxation data was expressed as the maximum relaxation response to papaverine (100 M) which elicited a complete reversal of bronchomotor tone. Cumulative concentration response curves were fitted to a 3 parameter logistic equation for the determination of potency EC50
and maximum relaxation. For each spasmolytic agent, an estimate of EC50 and Emax was obtained for each animal and then the geometric mean (95% Confidence interval) and mean (SD) of these parameter estimates was calculated. It is well established that concentration conforms to a lognormal distribution.
Statistical Analysis
Unless otherwise specified, parameter estimates are presented as mean + SD and the number of animals used is indicated in the table figure legends. Cumulative concentration-response curves were fitted to a 3 parameter logistic equation (GraphPad Prism version 5). Relaxant potency is expressed as geometric mean and 95% confidence interval. For the analysis of synergy, the interaction index (alpha) and additive response for each concentration pair was calculated following simultaneous solution of the intercept equation and the sigmoidal concentration-response relationship for each spasmolytic agent using SAS version 9.3. A single sample t-test was used to determine evidence of synergy by comparing alpha with the population mean of unity. Comparisons between mean values were deemed statistically significant when P < 0.05. A Benjamini-Hochberg multiple comparison test was used to adjust P values (InvivoStat version 3.1). We also undertook an additional statistical analysis of data presented in Table 1 . The contractile response of each component spasmogen (as a % of the total response) was compared between bath (within group), agonist (within group in the instance when 3 different contractile agonists were used) and their interaction (bath x agonist) to assess regional trachea differences in contractile potency. The subject (i.e animal) This article is protected by copyright. All rights reserved.
was a blocking factor to control for between animal variability. Data was analyzed using SAS version 9.3.
Validity of animal species or model selection
Tracheal tissue from guinea-pig was used in these studies. The guinea-pig is a suitable model to study the action of spasmolytic agonists. Bronchodilator drugs including beta2-adrenoceptor agonists and muscarinic receptor antagonists inhibit contraction in guinea-pig"s and are clinically effective. We have previously shown that the dual phosphodiesterase 3 and 4 inhibitor, RPL554, is a functional antagonist in this species and we have gone on to demonstrate the clinical effectiveness of this drug in subjects with asthma and COPD, again highlighting the utility of this model in the context of understanding the pharmacology of respiratory drugs. Furthermore, like human airways, guinea-pig trachea responds to spasmogenic agents including histamine and LTC 4 , which are spasmogenic agents used in this study.
Ethical Statement
Ethical approval for the work undertaken in this study was granted by local Animal Welfare Ethical Review Board, King"s College London and permissible under a United Kingdom Home Office approved project licence (PPL70/7498).
Animals
Male Dunkin Hartley guinea-pigs (250-300 g, 6 -8 weeks, Harland UK).
Housing and Husbandry
Animals were housed in groups of six within a Home office (United Kingdom) designated Biological Services unit with a 12 h night/day light cycle and access to food and water ad libitum. The cages contained soft bedding and environmental enrichment for welfare purposes and the animals were allowed to acclimatize to this environment for 5-7 days after arrival to the Unit before use.
Tissue preparation
Male Dunkin Hartley guinea-pigs (250-300 g) were humanely killed by cervical dislocation.
Trachea and lungs were removed immediately and placed in ice-cold Krebs-Henseleit solution. The composition of the Krebs-Henseleit solution, which was gassed with 95% 0 2 : 5% CO 2 and maintained at 37 0 C, was (mM): NaCl 118.0, KCI 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 25.0, glucose 11 and CaCl 2 2.5 in the absence or presence of Indomethacin (5 M).
Following careful removal of adherent fat and connective tissue, the trachea was cut into rings (approximately 2 mm i.d and between 1-2 mm thickness). Either four or eight tracheal rings were taken from each animal depending on the experiment undertaken to one or two of our quadruple organ bath set-ups, respectively. In the case when eight preparations were used from the same animal, then two different experiments were conducted between the set of four tracheal preparations. There is no evidence of regional differences in relaxant or contractile potency along the trachea (Preuss et al., 1998 
Experimental Procedures

Contractile responses
After a 30 to 40 min equilibration period, tissues were contracted with 0.1 and 1 M carbachol to confirm tissue viability. Following a washout period of 30-40 min some tissues were contracted with increasing concentrations of carbachol in order to obtain an estimate of contractile potency (EC50). After the contractile response had plateaued, tissues were subjected once more to another washing routine and left for a further 30-40 min to equilibrate.
In other experiments, guinea-pig tracheal tissues were contracted with either carbachol (10 x EC50), or combinations of spasmogens added sequentially as follows:
histamine (10 M) and carbachol (10 M) in the absence or presence of leukotriene (LTC) 4 (100 nM), the latter added first to the organ both. In other experiments, tracheal tissue was contracted with a combination of KCl (40 mM) and carbachol (10 M) added sequentially in the absence or presence of LTC 4 (100 nM) applied first.
In experiments conducted with LTC 4 , tissues were pre-incubated for 45 min with L- inhibitor, RPL554. In other experiments, RPL554 was added in a cumulative fashion in tissues after cumulative additions of beta2-agonist or muscarinic receptor antagonist to provide evidence of additional relaxation. In further experiments, combinations (ratio) of spasmolytic agents were used and included ipratropium bromide and salbutamol (1:5.7), to mimic the dose combination used clinically in nebulizers by subjects with asthma (McNamara et al., 2012) ,glycopyrrolate and RPL554 (1:9, 1:24, 1:226), roflumilast and cilostamide (1:1), and siguazodan and cilostamide (1:1). This approach was used in order to determine additivity or synergy with such combinations of relaxant agonists. We also chose to administer increasing concentrations of a combination of PDE3 and PDE4 inhibitor in a 1:1 ratio, rather than in a sequential fashion (i.e. a single concentration of one inhibitor followed by increasing cumulative concentrations of another) to avoid confounding due to loss of tracheal tension to either inhibitor in a sequence when comparing relaxation responses between combination of PDE inhibitors and RPL554. Maximum relaxation was achieved with papaverine.
Analysis of Synergy
We took the opportunity of analyzing the data collected for evidence of a synergistic interaction between different spasmolytic agents in some of the experiments undertaken with different experimental conditions, using a mathematical approach to describe a synergistic interaction between RPL554 and glycopyrrolate in human bronchial tissue (Calzetta et al., 2013) . To determine synergy for any combination of drugs, denoted a and b respectively, requires the simultaneous solution of the cumulative response relationship for both drugs i.e.
f(A) and f(B) and the intercept equation described below:
Where EmA and EmB represent the maximum relaxation response to drug alone; EC50 A and alpha <1 or =1 denote synergy or additivity, respectively. (Berenbaum, 1989; Lamarre & Tallarida, 2008; Tallarida, 2012) .
Materials
Ipratropium bromide, salbutamol sulphate, carbachol chloride, histamine chloride, potassium chloride, glycopyrrolate and formoterol fumarate, were prepared in Krebs-Henseleit solution.
CFTRinh172, iberiotoxin, RPL554, roflumilast, cilostazol, and cilostamide were prepared using dimethylsulphoxide ( 
Results
RPL554 functional antagonism studies
Four different spasmogenic conditions were employed to increase bronchomotor tone, namely, 1) combination of histamine (10 M) and carbachol (10 M); 2) the combination of LTC 4 (100 nM), histamine (10 M) and carbachol (10 M) (Fig 1) ; 3) the combination of KCL (40 mM) and carbachol (10 M) (Fig2 A,C,E,G); and 4) the combination of LTC 4 (100 nM), KCL (40 mM) and carbachol (10 M) (Fig 2B,D ,F,H). The cumulative tension generated for each contractile agonist and the degree of contraction expressed as a percentage of the total contractile response for each condition is summarized in Table 1 . There was no significant difference in the magnitude of the total contractile response induced by different combinations of these contractile agonists (Table 1) . We also compared the contractile response (% Emax, Table 1 ) for each component in the combination to assess for regional variation in contractile activity along the trachea. There was no evidence of a significant difference in regional variation in tracheal contractile response to the spasmogens used in this study (P > 0.05, Table 1 footnote).
In each of these conditions, RPL554, ipratropium bromide, salbutamol and the combination of ipratropium bromide and salbutamol (1:5.7; "Combivent") caused a concentration dependent relaxation response. The degree of reversal was dependent upon the combination of spasmogens used to induce bronchomotor tone. RPL554 fully reversed tracheal tension irrespective of which spasmogenic condition was used (Table 2, Fig 1-2 ). As anticipated, there was a reduction in relaxant potency with RPL554 particularly in tissues contracted with potassium ions (Fig 2, Table 2 ), but nonetheless, full reversal of tone was always achieved. Similarly, whilst the relaxant activity of salbutamol, ipratropium bromide and their combination was reduced in tissues exposed to KCL (40 mM), yet full relaxation was achieved with the further addition of RPL554 (Fig 2, Table 2 ). The relaxant potency and maximum relaxation response (expressed as a percentage of reversal of papaverine Emax) for each spasmolytic agent is summarized in Table 2 .
The contractile response of tracheal tissue to LTC 4 , histamine and carbachol was not fully reversed by the long acting muscarinic receptor antagonist, glycopyrrolate (EC50; 2.9 (0.9 -8.8) nM, n=6; Relaxation % Emax papaverine, mean, SD; 61 + 10 %, Emax), however, the addition of RPL554 fully reverse bronchomotor tone (data not shown).
The effect of PDE3 and PDE4 selective inhibitors on bronchomotor tone
We compared the potency of a range of PDE inhibitors in tissue contracted with carbachol (10 x EC50). The PDE3 inhibitor, siguazodan and the PDE4 inhibitor, roflumilast had lower relaxant activity at the concentrations tested with the maximum concentrations employed being at least 10-100 x greater than predicted from their isolated enzyme inhibitory potency ( Fig 3A) . As anticipated bronchodilators like salbutamol sulphate and formoterol fumarate caused full relaxation, which was also observed with the PDE3 inhibitors, cilostamide and cilostazol as well as the dual inhibitor RPL554 (Fig 3, Table 3 ).
Bronchomotor tone induced by a combination of histamine (10 M) and carbachol (10 M) was not fully reversed by the beta2-agonists salbutamol and formoterol or the PDE3 selective inhibitors, or cilostamide (Fig 3B) , yet under these same conditions the dual PDE inhibitor, RPL554 were able to cause near maximum relaxation. The PDE4 selective inhibitor, roflumilast, had weak relaxant activity under these assay conditions. Unlike RPL554, a combination of cilostamide and roflumilast (1:1) did not fully reverse bronchomotor tone under these conditions (Fig 3B) . In additional experiments, cilostazol, a structurally related dihydroquinolinone , did not produce full relaxation (EC50, 95% CI: 9173
(962 -87440) nM; % Emax papaverine (SD): 64 (17), N = 5) alone or in 1:1 combination with roflumilast (EC50 value was not estimable with confidence; Emax 39 (11), N = 5).
In tissues contracted with LTC4 (100 nM), histamine (10 M) and carbachol (10 M)
both cilostamide alone and in a 1:1 combination with roflumilast (1:1) or the structurally unrelated PDE3 inhibitor, siguazodan either alone and in combination with roflumilast (1:1) also demonstrated lower relaxant activity than RPL554 alone in tissues contracted ( Fig 3C,D respectively; Table 3 ). For completeness, cilostazol either alone (EC50, 95 % CI; 2919 (694 -12460) nM; % Emax papaverine, SD; 66 (12), N = 6) or in combination with roflumilast in a 1:1 ratio (1890 (77 -46400) nM, 52 (12), respectively, N = 6) did not completely reverse bronchomotor tone under these experimental conditions.
Interaction studies
We were afforded the opportunity of investigating whether the combination of different spasmolytic agents produced a synergistic relaxation response under the different contractile conditions employed. The relaxation response to "combivent" (ipratropium bromide and salbutamol, 1:5.7) was analysed for any synergistic interaction between the two component bronchodilators in tissues contracted with LTC4, histamine and carbachol (Fig 4A, B) and LTC4, KCL and carbachol (Fig 4C,D) . The data presented in Fig 4A and 4D were re-drawn from the data presented in Fig 1. The zero interaction (additive) relationship for each concentration of "combivent" was calculated as described in the methods (Fig 3B, 3D ; blue line). There appears to be evidence of a greater relaxation response with the combination of ipratropium bromide and salbutamol as evidence by a leftward and downwards shift of the concentration-response curve to this combination compared with the additive response, indicative of a synergistic interaction. The magnitude of this difference between the observed response and the additive response was significant at concentrations greater than 30 nM (% relaxation, mean (SD); 25.4 (9) *, 22.6 (6.6) *, 25.2 (6.6) * and 23.6 (6.6), respectively, P < 0.05 unadjusted, *P < 0.05, Benjamini-Hochberg procedure). The interaction index (alpha) was inestimable because the relaxation response for the combination exceeded the maximum response to either drug alone. This synergistic interaction was absent in tissues contracted in the presence of KCL (Fig 3D) .
We also evaluated the effect of a combination of RPL554 and glycopyrrolate under different contractile conditions and found evidence of synergy (Table 4) , as assessed by alpha values less than unity, and greater relaxation response compared with the additive response (i.e. zero interaction effect), for selective concentration pairs of different combination ratios in tissues contracted and LTC 4 (100 nM), histamine (10 M) and carbachol (10 M) ( Fig   5A, C,E) and with histamine (10 M) and carbachol (10 M) (Fig 5B, D, F) . We also observed a synergistic interaction between glycopyrrolate and RPL554 in tissues exposed to high concentration of potassium ions (Table 4 , Fig 6) . Thus, irrespective of the contractile conditions employed, evidence of synergy between these two bronchodilators was observed.
Further studies
We evaluated the effect of selective inhibitors of CFTR and maxi-K calcium activated potassium channels on airway smooth muscle relaxation to agents that elevate intracellular cyclic AMP in view of the purported role these ion channels in this response. The relaxant potency (data not shown) to salbutamol or RPL554 was not significantly altered by a CFTR inhibitor, CFTRinh 172 (10 M) or the calcium-activated potassium channel blocker, iberiotoxin (100 nM) (Fig 7) .
Discussion
In this study, RPL554 produced maximal airway smooth muscle relaxation irrespective of the conditions used to induce contraction of guinea-pig isolated trachea. In addition RPL554 Clinical studies have demonstrated the ineffectiveness of oral or inhaled PDE4
inhibitors to act as acute bronchodilators at doses which inhibit indices of the inflammatory response or disease process (Grootendorst et al., 2003; Engelstaetter et al., 2005; Rabe et al., 2005; Fabbri et al., 2009; Singh et al., 2010) . In contrast, inhaled or intravenously administered PDE3 inhibitors have been demonstrated to cause bronchodilation in subjects with asthma (Fujimura et al., 1997; Myou et al., 2003) . Furthermore, RPL554, a dual PDE 3 and 4 inhibitor produced bronchodilation in asthmatic and COPD patients (Franciosi et al., 2013) . These clinical studies point to the importance of PDE3 rather than PDE4 as the major isoform which controls the levels of intracellular cyclic AMP within airway smooth muscle cells in humans. However, the expression of PDE3A in endobronchial biopsies was reduced by 2 fold in asthmatic subjects compared with healthy controls. The expression pattern for PDE4 in endobronchial biopsies from patients with asthma was not described in this study, possibly because the levels were not altered between the groups (Yick et al., 2013) . PDE gene expression has been measured in airway smooth muscle cells maintained in culture.
The expression of PDE4D was increased and PDE3A unchanged in cultured airway smooth muscle obtained from subjects with asthma compared with healthy control subjects (Trian et al., 2011; Lin et al., 2015) .
The PDE activity profile in homogenates of human airway tissue also confirms the presence of PDE3 and PDE4 activity, although differences in expression patterns have been reported by different laboratories (de Boer et al., 1992; Cortijo et al., 1993; Torphy et al., 1993 ) which might be due to regional differences in the expression pattern of PDEs within the respiratory tract, although for PDE3 this seems unlikely in view of the relaxation response seen with a PDE3 inhibitor in human airways irrespective of anatomical location (de Boer et al., 1992; Torphy et al., 1993) . PDE4 accounted for the majority of total PDE activity found in tracheal smooth muscle cells from non-asthmatic subjects (Billington et al., 2008) , whilst PDE3A and to a significantly lesser extent, PDE4D, was shown to be expressed in airway smooth muscle cells from intrapulmonary airways from non-asthmatic subjects (Trian et al., 2011) . Neverthless, the expression of PDE4D was increased in airway smooth muscle cells derived from subjects with asthma (Trian et al., 2011) . The inhibition of PDE4, but not PDE3, using subtype selective inhibitors (Trian et al., 2011) , or siRNA for PDE4D5 (Billington et al., 2008) augmented cyclic AMP levels in response to beta2-adrenoceptor stimulation, possibly suggesting a major role for this splice variant which represents a fraction of the total PDE4 pool in human airway smooth muscle cells, in the control of cyclic AMP levels following acute stimulation of the beta2-adrenoceptor.
Functional studies confirm clinical observations that in general PDE4 inhibitors including rolipram and RP73401 produce modest relaxation of human isolated airways, whereas greater relaxant activity is observed with PDE3 inhibitors including siguazodan.
However, these functional responses are dependent on the degree of bronchial or tracheal tone and the spasmogenic agent used to contract human airway tissue and therefore is context dependent. In general, as airway contractility is increased the relaxant activity of PDE4 inhibitors like rolipram is reduced to a greater extent than PDE3 inhibitors like siguazodan (Qian et al., 1993; Rabe et al., 1993; Torphy et al., 1993; Naline et al., 1996; Schmidt et al., 2000) . Furthermore, this context dependence might also explain why in some studies, both PDE4 inhibitors (Qian et al., 1993; Naline et al., 1996) and PDE3 inhibitors (Torphy et al., 1993) augmented the relaxation response to isoprenaline.
Similar to these findings in man, tracheal tissue from the guinea-pig also expresses both PDE3 and PDE4 isoenzymes and the relaxation response to rolipram and the PDE3 inhibitor, CL-930, was biphasic and the first phase response was relatively modest (Harris et al., 1989) . The relaxation or functional antagonism exerted by PDE3 and PDE4 inhibitors was also dependent on the spasmogenic condition employed, but when combined gave a greater inhibitory effect than either inhibitor alone (Turner et al., 1994; Underwood et al., 1994; Bernareggi et al., 1999) . The nature of the biphasic response reported with rolipram is unclear, but newer PDE4 inhibitors including roflumilast and cilomilast also produced weak or modest reversal of tone in guinea-pig trachea (Bundschuh et al., 2001; Kobayashi et al., 2012) . The role of PDE4 in airway smooth muscle might be dependent on the spasmogens used to contract tissues. For example, contractile responses induced by carbachol, but not serotonin, KCL and arginine vasopressin is significantly reduced in PDE4D gene ablated mice, or in tracheal preparations from wild type mice treated with rolipram, that was specifically dependent upon functional antagonism exerted by endogenously released PGE2 (Mehats et al., 2003) . Hence, we also evaluated the relaxant activity of RPL554 in tissues contracted with various combinations of spasmogens.
In view of the possibility that the contribution of different PDE isoforms for the regulation of cyclic AMP levels within airway smooth muscle may vary depending on disease status and to the degree of airway tone, it would seem advantageous to inhibit both PDE3 and PDE4 in airway smooth muscle and thereby provide more effective bronchodilation in most circumstances. In this study we have demonstrated that the relaxant activity of PDE3 and PDE4 selective inhibitors is dependent upon the contractile agonists used to induce tracheal airway smooth muscle contraction. The PDE3 selective inhibitors cilostamide and cilostazol, produced maximal relaxation in tissues contracted with carbachol (10x EC50), whereas cilostamide was less effective in tissues contracted with different combinations of spasmogenic agonists. In all conditions, the PDE4 inhibitor roflumilast only produced a modest relaxation. We did not use concentrations of roflumilast greater than 1 M in view of the sub nanomolar affinity of this drug for PDE4 (Bundschuh et al., 2001) .
The combination of a PDE3 and PDE4 inhibitor in a 1:1 ratio produce a comparable relaxation response compared with either inhibitor alone. However, RPL554 demonstrated greater relaxant activity under all spasmogenic conditions used highlighting a novel finding in that the relaxation induced by RPL554 is more than merely the combined inhibition of separate PDE3 and PDE4 subtype selective inhibitors. The greater relaxant activity of RPL554 might be due its greater inhibitory potency for PDE3 (human platelet PDE3, 0.4 nM) (Boswell-Smith et al., 2006) compared with cilostamide (human recombinant PDE3A; 27 nM) (Sudo et al., 2000) ; alternatively the combined inhibition of PDE3 and PDE4 by a single molecular structure may be more optimal than the combination of two separable isoform selective PDE inhibitors. Alternatively, RPL554 might have a more favourable pharmacodynamic profile within airway smooth muscle cells compared with cilostamide, although this seems unlikely in view of the ability of cilostamide to fully reverse bronchomotor tone induced by carbachol (10x EC50). Whether RPL554 has additional properties other than inhibition of phosphodiesterase 3 and 4 is currently unknown, although we can rule out a role for calcium activated K channels and the cystic fibrosis transmembrane receptor (CFTR), given that selective inhibitors of these channels (Jones et al., 1990; Norez et al., 2014) did not significantly alter the relaxation response to RPL554.
We also compared the effect of RPL554 to induce spasmolysis when combined with the muscarinic receptor antagonist, ipratropium bromide, the beta2-adrenoceptor agonist, salbutamol alone, and in a 1:5.7 combination which has been used to mimic the effects of the clinically used "Combivent" preparation in whole animal studies (McNamara et al., 2012) .
As anticipated, the relaxant activity of salbutamol and ipratropium bromide and their combination was dependent upon the mixture of different contractile agonists used to induce bronchomotor tone. In tissues which were exposed to KCL (40 mM), it is clear that the relaxant activity of these spasmolytics was reduced, but in all cases, additional inhibition of bronchomotor tone was achieved with RPL554. If these results are translated to patients, one might speculate that dual PDE inhibitors, like RPL554 could offer additional bronchodilator activity in severely constricted airways. This would be consistent, at least in part, with the clinically effective bronchodilation observed with RPL554 in subjects with asthma and COPD (Franciosi et al., 2013) . In an analogous scenario, the combination of a LABA and a LAMA appears to be superior than either component drug alone in terms of improvement in trough FEV1 (Buhl et al., 2015) , and the clinical effectiveness of a MABA (Wielders et al., 2013) in patients with COPD, suggest that single molecule "dual" inhibitors may be as effective, if not more effective than monocomponent drugs. We have previously reported that RPL554 can elevate intracellular levels of cyclic AMP in human neutrophils (BoswellSmith et al., 2006) , and other studies have shown that combination of a PDE3 with PDE4 inhibitor was more effective than either inhibitor alone in suppressing the generation of inositol(1,4,5) triphosphate induced by histamine and carbachol, though more effective against the former (Challiss et al., 1998) . Hence, RPL554 offers the possibility of inhibiting PDE3 and PDE4 isoenzymes functionally more optimally than selective PDE 3 and 4 inhibitors used in combination.
We did not extensively investigate the intracellular mechanism by which RPL554
gives rise to this additional relaxation response under different spasmogenic conditions, although we can rule out an involvement of membrane hyperpolarization via opening of calcium activated potassium channels or CFTR. The reduction in relaxant activity observed with beta2-adrenoceptor stimulation in tissues contracted with potassium chloride (Janssen et al., 2004) and this study, could be explained by differences in calcium signalling within airway smooth muscles by depolarization versus agonists of G-protein coupled receptors (Perez & Sanderson, 2005) . In contrast, RPL554 might retain the capacity to elevate intracellular levels of cyclic AMP downstream of a PKC dependent impairment of beta2-adrenoceptor coupling and/or desensitization (Pitcher et al., 1992) .
Drugs used in combination have the potential to act in an additive or synergistic fashion and clinical evidence for synergism has been demonstrated elsewhere for combinations of anaesthetics or pain relieving medication (Montes et al., 2000; Manyam et al., 2006; Filitz et al., 2008) . The question of whether mechanistically distinct spasmolytics can act additively or synergistically has not been fully addressed using mathematical approaches that have been developed to investigate this phenomenon (Berenbaum, 1989; Lamarre & Tallarida, 2008; Tallarida, 2012) . Previous studies have suggested a synergistic interaction between beta2-adrenoceptor agonists and muscarinic receptor antagonists, though not analysed rigorously using a mathematical approach of this phenomenon (Rossoni et al., 2007; McNamara et al., 2012; Smit et al., 2014) . We found some evidence of synergy for various combinations of salbutamol and ipratropium bromide, and between RPL554 and glycopyrrolate, with the response for some concentration pairs greater than would be expected if there was an additive effect (zero interaction). The later observed consistent with a previous study in human bronchial airways (Calzetta et al., 2015) . Interestingly, this effect was lost for the combination salbutamol/ipratropium bromide but not RPL554/glycopyrrolate, in tissues contracted with KCL (40 mM), again leading to the speculation that RPL554 is bypassing impaired beta2-adrenoceptor signalling and in this respect highlights another novel finding with the ability of this dual PDE3 and PDE4 inhibitor to maintain synergism under conditions in which a synergistic action to beta2-adrenoceptor stimulation is lost. It has been
proposed that synergy between the relaxant effects of indacaterol and glycopyrronium is mediated in part via the opening of calcium activated K channels (Kume et al., 2014) . Under the conditions employed in our study, the high concentration of potassium would render these channels inoperable and hence hyperpolarization and closure of voltage operated calcium channels would not occur. This would be expected to functionally antagonise the relaxation response to combination ipratropium bromide and salbutamol and hence, could explain this loss of synergy. However, in our studies iberiotoxin did not impair the functional response to salbutamol or RPL554, ruling out a role for these ion channels in the relaxation response to these cyclic AMP elevating drugs. The change in responsiveness to salbutamol was small compared with other reported studies using charybdotoxin or iberiotoxin and may be related to differences in the contractile stimulus employed in this study (Jones et al., 1990; Corompt et al., 1998) . However, the importance of these ion channels in mediating relaxation of airway smooth muscle by beta2-adrenoceptor agents is not universally accepted (Huang et al., 1993; Corompt et al., 1998; Janssen, 2002; Janssen et al., 2004; Sausbier et al., 2007) .
Moreover, calcium channel blocking drugs do not appear to modify the relaxation to isoprenaline in isolated airway preparations (Janssen et al., 2004) .
In summary, in circumstances where the spasmolytic activity of a muscarinic antagonist or beta2-adrenoceptor agonist alone, or in combination is reduced, we have shown that, i) RPL554 provides additional smooth muscle relaxation when administered subsequently, ii) there was evidence of specific synergism between that RPL554 and glycopyrrolate, iii) that the relaxation produced by RPL554 was greater than that produced by the combination of a selective PDE3 and PDE4 inhibitor and iv) that the mechanism of airways smooth muscle relaxation is not due to activation of maxi-K channels or CFTR activation. This suggests that RPL554 could not only provide additional benefit to standard care in asthma and COPD, but under certain circumstances demonstrate a synergistic interaction for smooth muscle relaxation beyond that achieved with salbutamol. The additional anti-inflammatory properties described for RPL554 highlight its potential in the treatment of respiratory diseases. Values expressed as mean + SD with number of animals denoted in parenthesis. † Cumulative tension generated by spasmogens. † † Contractile response to a spasmogen is expressed as a percentage of the total contractile response. We also compared the contractile response (% Emax) for each component in the combination to assess for regional variation in contractile activity along the trachea. Contractile response was analyzed by fitting to a model defined by fixed factors (organ bath) with the animal as a blocking factor. There was no significant bath effect in the case of Histamine/Carbachol and KCL/Carbachol, or interaction between tissue randomized to organ bath and the agonist used in the combination LTC4/histamine/carbachol and LTC4/KCL/Carbachol (P > 0.05), highlighting a lack of regional variation in response to spasmogens. . Synergistic interaction between RPL554 and glycopyrrolate under various contractile conditions, (A) Concentration-relaxation response curve to glycopyrrolate, RPL554 alone or in combination (1:9, 1:24) in tissues contracted with LTC4 (100 nM), histamine (10 M) and carbachol (10 M). Data expressed as mean + SEM, in tracheal tissue from N = 5-6 animals. Comparison of the relaxation concentration-response curve for different combination ratios glycopyrrolate and RPL554 (C, 1:9 respectively and E, 1:24 respectively) and the zero interaction relationship (additive) for each concentration pair. Concentration-relaxation response curve to glycopyrrolate, RPL554 alone or in combination (1:24, 1:226) in tissues contracted with (B) histamine (10 M) and carbachol (10 M). Data expressed as mean + SEM, in tracheal tissue from N = 5-7 animals. Comparison of the concentration-response curve to the observed response to the different combination ratios of glycopyrrolate and RPL554 (D, 1:249 respectively and E, 1:226 respectively) and the zero interaction relationship (additive) for each concentration. Data represented in the left and right panels of this figure was obtained from different cohorts of animals. There was evidence for a synergistic interaction between glycopyrrolate and RPL554 (see Table 4 ) as reflected by a significant interaction index (alpha) and difference between the observed and additive relaxation response (% mean (SD) difference). Table 4 ) as reflected by a significant interaction index (alpha) and difference between the observed and additive relaxation response (% mean (SD) difference). 
